Entelos Acquires Iconix in $14.1M Deal | GenomeWeb
Entelos yesterday said that it has acquired toxigenomics firm Iconix Biosciences in an all-share transaction initially valued at $14.1 million but with the potential of rising to $39 million.
 
Foster City, Calif.-based Entelos said that it would issue up to 12,776,658 shares of its stock to Iconix shareholders and a potential maximum earn-out payment of $25 million if certain milestones are achieved within one year following the close of the deal today. The deferred consideration also would be paid in Entelos shares.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.